5.33
+1.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Phathom Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Phathom Pharmaceuticals is based in Florham Park, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PHAT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $175.1m and a net loss of $221.2m. At that date it held total assets of $259.1m and shareholders' equity of −$438.2m.
We are a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of molecules that block acid secretion in the stomach. VOQUEZNA is the only PCAB currently approved for marketing and sale in the United States.
We began U.S. commercialization of VOQUEZNA for the treatment of erosive gastroesophageal reflux disease, or Erosive GERD, and Helicobacter pylori, or H. pylori, infection, and VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of H. pylori infection, in November 2023. The U.S. Food and Drug Administration, or FDA, approved VOQUEZNA for the relief of heartburn associated with Non-Erosive GERD, the largest category of GERD, in July 2024.
Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited, or Takeda, and is marketed in multiple countries outside the United States. We licensed U.S., European and Canadian rights to vonoprazan from Takeda in 2019. We are independently commercializing VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK in the United States.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Oct 2019
- Employees
- 371
- Website
- phathompharma.com ↗
- Head office
- 100 CAMPUS DRIVE,, FLORHAM PARK, NJ, 07932
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Michael ColaIndependent Chairman of the Board$343,597
- Mr. Steven BastaPresident, Chief Executive Officer, Director, since 2025
- Dr. Azmi NabulsiCo-Founder, Chief Operating Officer$1.6m
- Mr. Sanjeev NarulaChief Financial and Business Officer
- Ms. Anne CookChief Legal Officer and Corporate Secretary
- Mr. Frank KarbeIndependent Director$297,555
- Ms. Heidi KunzIndependent Director$304,430
- Dr. Asit ParikhIndependent Director$296,930
- Mr. Theodore SchroederIndependent Director
- Mr. Mark StenhouseIndependent Director$296,097
- Dr. James TopperIndependent Director$284,430
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 54
- Social
- 30
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Phathom Pharmaceuticals Inc has several notable strengths:
Weaknesses
- Despite its strengths, Phathom Pharmaceuticals Inc also faces certain weaknesses:
Opportunities
- Phathom Pharmaceuticals Inc can capitalize on the following opportunities:
Threats
- Phathom Pharmaceuticals Inc faces the following threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.